Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

NCT06563869 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: PEG-rhG-GSF

Sponsor

The First Affiliated Hospital with Nanjing Medical University